MSBI:NASDAQMidland States Bancorp, Inc. Analysis
Data as of 2026-07-16 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Midland States Bancorp (MSBI) is trading at $31.70, comfortably above its 20‑day SMA (30.44) and 50‑day SMA (28.97) while still below the 200‑day SMA (22.67), indicating a short‑term bullish bias within a longer‑term uptrend. Momentum signals are mixed: the RSI sits at 67, edging toward overbought territory, and the MACD histogram has turned negative with a bearish signal line crossover, while trading volume has been decreasing, suggesting waning short‑term enthusiasm. The stock offers an attractive 4.17% dividend yield, but the payout ratio exceeds 100%, raising concerns about sustainability. Valuation metrics are mixed – a trailing P/E of 26.4x outpaces the industry average of 18x, yet the forward P/E drops to 10.1x, and the DCF model implies a fair value far above the current price, creating a valuation paradox. Revenue growth remains robust at 14% YoY, and the forward EPS projection (3.14) more than doubles the trailing EPS (1.20), supporting a growth narrative. However, the bank’s beta (~0.8) and 30‑day volatility of nearly 25% signal higher price swings than the broader market, and the declining volume trend may limit liquidity in rapid moves. Recent material news is limited to a scheduled Q2 earnings release on July 23, providing little immediate catalyst. Overall, the stock sits at a crossroads between short‑term technical weakness and longer‑term growth fundamentals, with dividend appeal tempered by payout concerns.
Market Outlook
Short Term
< 1 yearKey Factors
- Price near resistance with bearish MACD crossover
- RSI approaching overbought levels
- Decreasing trading volume
Medium Term
1–3 yearsKey Factors
- Strong revenue growth and improving forward earnings
- High dividend yield but unsustainable payout ratio
- Valuation disparity between trailing and forward P/E
Long Term
> 3 yearsKey Factors
- Long‑term growth prospects in loan and wealth‑management segments
- Potential price correction toward DCF‑derived intrinsic value
- Low beta indicating relative resilience in broader market moves
Key Metrics & Analysis
Financial Health
Technical Analysis
Valuation
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.